MCID: THY125
MIFTS: 51

Thyroid Gland Medullary Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Gland Medullary Carcinoma

MalaCards integrated aliases for Thyroid Gland Medullary Carcinoma:

Name: Thyroid Gland Medullary Carcinoma 12
Medullary Thyroid Carcinoma 12 15
Medullary Carcinoma of the Thyroid Gland 12
Ultimobranchial Thyroid Tumour 12
Ultimobranchial Thyroid Tumor 12
Thyroid Medullary Carcinoma 15
Thyroid Cancer, Medullary 43

Classifications:



External Ids:

Disease Ontology 12 DOID:3973
MeSH 43 C536914
NCIt 49 C3879
SNOMED-CT 67 32913002
UMLS 71 C0238462

Summaries for Thyroid Gland Medullary Carcinoma

Disease Ontology : 12 A thyroid gland carcinoma that has material basis in parafollicular cells.

MalaCards based summary : Thyroid Gland Medullary Carcinoma, also known as medullary thyroid carcinoma, is related to multiple endocrine neoplasia, type iia and multiple endocrine neoplasia, type iib. An important gene associated with Thyroid Gland Medullary Carcinoma is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Tyrosine and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include thyroid, pituitary and testes, and related phenotype is digestive/alimentary.

Related Diseases for Thyroid Gland Medullary Carcinoma

Diseases related to Thyroid Gland Medullary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 377)
# Related Disease Score Top Affiliating Genes
1 multiple endocrine neoplasia, type iia 33.9 RET NTRK1 MEN1 GDNF CALCA
2 multiple endocrine neoplasia, type iib 33.3 RET NTRK1 MEN1 GDNF CALCA
3 thyroid carcinoma 32.9 TG RET NTRK1 CALCA
4 thyroid gland papillary carcinoma 31.7 TG RET MIR183
5 goiter 31.7 TG SST RET CALCA
6 rare tumor 31.6 SST RET
7 nodular goiter 31.5 TG RET CALCA
8 neuroma 31.4 RET GDNF CALCA
9 differentiated thyroid carcinoma 31.2 TG RET NTRK1
10 parathyroid adenoma 31.2 RET MEN1 CHGA CALCA
11 papillary carcinoma 31.1 TG RET NTRK1 CHGA CALCA
12 adenoma 31.1 SSTR5 SSTR2 SST RET MEN1 CHGA
13 thyroid gland disease 31.1 TG SST RET MIR183 CALCA
14 primary hyperparathyroidism 31.0 RET MEN1 GAST CHGA CALCA
15 hirschsprung disease 1 30.9 RET NTRK1 GDNF CALCA
16 malignant pheochromocytoma 30.9 SST CHGA CALCA
17 paraganglioma 30.9 TG SST RET MEN1 CHGA CALCA
18 pituitary tumors 30.8 SSTR5 SST MEN1
19 neuroendocrine tumor 30.8 SSTR2 SST RET MEN1 GAST CHGA
20 hyperthyroidism 30.8 TG SST CALCA
21 carney complex variant 30.8 SST RET MEN1
22 thyroiditis 30.8 TG RET CALCA
23 fetal adenoma 30.7 TG CALCA
24 extra-adrenal pheochromocytoma 30.7 RET CHGA
25 neuroendocrine carcinoma 30.7 SST MEN1 GAST CHGA CEACAM5 CALCA
26 endocrine gland cancer 30.7 SST RET MIR31 MIR183 GAST CHGA
27 parathyroid carcinoma 30.6 RET MEN1 CALCA
28 carcinoid tumors, intestinal 30.6 SSTR2 SST MEN1 GAST CHGA
29 multiple endocrine neoplasia 30.6 RET MEN1 GDNF CALCA
30 duodenal somatostatinoma 30.5 SST MEN1
31 endemic goiter 30.5 TG CALCA
32 multiple mucosal neuroma 30.4 RET NTRK1 MEN1 GDNF CALCA
33 thyroid carcinoma, familial medullary 30.4 TG SSTR5 SSTR2 SSTR1 SST RET
34 small cell carcinoma 30.4 GAST CHGA CALCA
35 mucoepidermoid carcinoma 30.4 TG CHGA CEACAM5 CALCA
36 megacolon 30.4 RET NTRK1 GDNF
37 follicular adenoma 30.4 TG RET NTRK1 MEN1 CALCA
38 adrenal carcinoma 30.4 SST MEN1 CHGA
39 von hippel-lindau syndrome 30.4 RET MEN1 CHGA
40 intestinal obstruction 30.4 SST RET GDNF CEACAM5
41 multiple endocrine neoplasia, type i 30.3 SST RET MEN1 GAST CHGA
42 ganglioneuroma 30.3 SST RET NTRK1 CHGA
43 hyperparathyroidism 30.3 RET MEN1 GAST CHGA CALCA
44 thyroid gland anaplastic carcinoma 30.2 TG RET
45 small cell cancer of the lung 30.2 SST MALAT1 GAST CHGA CEACAM5 CALCA
46 gallbladder disease 30.2 SST CEACAM5 CCKBR
47 parathyroid gland disease 30.1 TG RET MEN1 GAST CALCA
48 pituitary adenoma 30.1 SSTR5 SSTR3 SSTR2 SST MEN1 MALAT1
49 neuroblastoma 30.0 SSTR2 SST RET NTRK1 MEN1 MALAT1
50 somatostatinoma 29.9 SSTR2 SST MEN1 GAST CHGA CALCA

Graphical network of the top 20 diseases related to Thyroid Gland Medullary Carcinoma:



Diseases related to Thyroid Gland Medullary Carcinoma

Symptoms & Phenotypes for Thyroid Gland Medullary Carcinoma

MGI Mouse Phenotypes related to Thyroid Gland Medullary Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.23 CCKBR GAST GDNF MEN1 RET SST

Drugs & Therapeutics for Thyroid Gland Medullary Carcinoma

Drugs for Thyroid Gland Medullary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
2
Liraglutide Approved Phase 3 204656-20-2 44147092
3
Glucagon Approved Phase 3 16941-32-5
4 Gastrointestinal Agents Phase 3
5 Hormone Antagonists Phase 3
6 Hormones Phase 3
7 Glucagon-Like Peptide 1 Phase 3
8 Incretins Phase 3
9 Hypoglycemic Agents Phase 3
10 insulin Phase 3
11 Insulin, Globin Zinc Phase 3
12
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
13
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
14
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
15
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
16
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6 774
17
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
18
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
19
Tamoxifen Approved Phase 2 10540-29-1 2733526
20
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
21
Sodium citrate Approved, Investigational Phase 2 68-04-2
22
Pancrelipase Approved, Investigational Phase 2 53608-75-6
23
Melphalan Approved Phase 2 148-82-3 4053 460612
24
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
25
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
26
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
27
Pasireotide Approved Phase 2 396091-73-9 9941444
28
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
29
Iodine Approved, Investigational Phase 2 7553-56-2 807
30
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
31
Nintedanib Approved Phase 2 656247-17-5 56843413
32
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
33
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
34
Dacarbazine Approved, Investigational Phase 1, Phase 2 4342-03-4 5351166
35
Capecitabine Approved, Investigational Phase 1, Phase 2 154361-50-9 60953
36
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
37
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
38
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
39
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
40
Levodopa Approved Phase 2 59-92-7 6047
41
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
42
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
43
Imetelstat Investigational Phase 2 868169-64-6
44
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
45 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
46 Immunologic Factors Phase 2
47 Anti-Bacterial Agents Phase 2
48 Anti-Infective Agents Phase 2
49 Immunosuppressive Agents Phase 2
50 Antibiotics, Antitubercular Phase 2

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Unknown status NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
2 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
3 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
4 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
5 Liraglutide in the Treatment of Type 1 Diabetes Mellitus Completed NCT01722266 Phase 3 Liraglutide;Placebo
6 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
7 A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma Unknown status NCT01118065 Phase 2 everolimus
8 Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas and Medullary Thyroid Carcinomas Completed NCT00026533 Phase 2 thalidomide
9 A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT01661179 Phase 1, Phase 2 Vandetanib 300mg
10 A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT02114658 Phase 2 Sorafenib (Nexavar,BAY43-9006)
11 Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma Completed NCT00467506 Phase 2 bispecific antibody and di-DTPA-131I
12 An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma. Completed NCT00098345 Phase 2 ZD6474 (vandetanib)
13 Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma Completed NCT01874873 Phase 2 Anlotinib
14 A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer Completed NCT00095836 Phase 2 Gefitinib
15 An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
16 Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma. Completed NCT01730638 Phase 1, Phase 2 • TF2 and 68 Ga-IMP-288
17 A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC) Completed NCT02614495 Phase 2 Surufatinib
18 Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 Alone or Combined With Doxorubicin and Peripheral Blood Stem Cell Rescue (PBSCR) in Medullary Thyroid Cancer (MTC) Grant Application Title: Radioimmunotherapy of MTC With Y-90 Humanized MN14 Anti-CEA Mab and Doxorubicin Completed NCT00004048 Phase 1, Phase 2 doxorubicin hydrochloride
19 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
20 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
21 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
22 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2 Sorafenib (nexavar)
23 Phase 2 of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer Completed NCT00510640 Phase 2 Sunitinib
24 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
25 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
26 A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma Completed NCT00098813 Phase 2 romidepsin
27 Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression Completed NCT01625520 Phase 2 SOM230 alone or in combination with RAD001.
28 Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
29 Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma Active, not recruiting NCT00390325 Phase 2 Sorafenib;Sorafenib Tosylate
30 Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma Active, not recruiting NCT00514046 Phase 1, Phase 2 Vandetanib
31 A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy. Active, not recruiting NCT01788982 Phase 2 Nintedanib;Placebo
32 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
33 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
34 A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma Terminated NCT00354523 Phase 1, Phase 2 Capecitabine (Xeloda);DTIC-Dome (Dacarbazine);Gleevec (Imatinib Mesylate)
35 A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC) Terminated NCT00923247 Phase 1, Phase 2 Bortezomib;Vandetanib
36 Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer Terminated NCT00100828 Phase 2 irinotecan hydrochloride
37 Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
38 Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer. Terminated NCT00647140 Phase 2
39 Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma Withdrawn NCT01736878 Phase 2 Sorafenib
40 Phase I Clinical Trial Using a Novel CCK-2/Gastrin Receptor-localizing Radiolabelled Peptide Probe for Personalized Diagnosis and Therapy of Patients With Progressive or Metastatic Medullary Thyroid Carcinoma Unknown status NCT03246659 Phase 1 111In-CP04;111In-CP04 with co-administration of gelofusine/gelaspan
41 A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA Completed NCT00027534 Phase 1
42 Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor Completed NCT00098943 Phase 1
43 A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
44 A Phase I Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Human Cultured Dendritic Cells in Patients With Metastatic Malignancies Expressing Carcinoembryonic Antigen Completed NCT00004604 Phase 1
45 B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
46 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
47 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study. Recruiting NCT02088645 Phase 1 177Lu-PP-F11N
48 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
49 Phase I Study of the Pharmacokinetics and Pharmacodynamics of ZD6474 in Combination With Docetaxel in Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
50 Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients Completed NCT01424878

Search NIH Clinical Center for Thyroid Gland Medullary Carcinoma

Cochrane evidence based reviews: thyroid cancer, medullary

Genetic Tests for Thyroid Gland Medullary Carcinoma

Anatomical Context for Thyroid Gland Medullary Carcinoma

MalaCards organs/tissues related to Thyroid Gland Medullary Carcinoma:

40
Thyroid, Pituitary, Testes, Lymph Node, Lung, Breast, Bone

Publications for Thyroid Gland Medullary Carcinoma

Articles related to Thyroid Gland Medullary Carcinoma:

(show top 50) (show all 3837)
# Title Authors PMID Year
1
Letter to the Editor: 18F-NaF not cited in the EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. 61
31741018 2020
2
Which Is the Optimal Scan Time of 18F-DOPA PET/CT in Patients With Recurrent Medullary Thyroid Carcinoma?: Results From a Dynamic Acquisition Study. 61
31977485 2020
3
18F-Fluoride (18F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines! 61
31754794 2020
4
Gastropharyngeal Anastomotic Leak in Medullary Thyroid Carcinoma Following Initiation of a Tyrosine Kinase Inhibitor: A Case Report of an Unusual Side Effect of Cabozantinib. 61
32037846 2020
5
Spindle epithelial tumour with thymus-like differentiation: report of two cases. 61
31530165 2020
6
Multiple endocrine neoplasia type 2B: Frequency of physical stigmata-Results of the GPOH-MET registry. 61
31724322 2020
7
An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients. 61
31297834 2020
8
Cardiac metastasis from medullary thyroid carcinoma: insights from multimodal molecular imaging and magnetic resonance imaging. 61
31397474 2020
9
Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma. 61
32031055 2020
10
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma. 61
31648931 2020
11
The role of molecular testing in the diagnosis of medullary thyroid cancer: A case report of oncocytic medullary thyroid carcinoma and review of the literature. 61
31727331 2020
12
Silencing of zinc finger protein 703 inhibits medullary thyroid carcinoma cell proliferation in vitro and in vivo. 61
31897207 2020
13
Revisiting the genotype-phenotype correlation in children with medullary thyroid carcinoma: A report from the GPOH-MET registry. 61
31925938 2020
14
Improved cell-specificity of adeno-associated viral vectors for medullary thyroid carcinoma using calcitonin gene regulatory elements. 61
32027681 2020
15
Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib. 61
31900481 2020
16
Calcitonin as a biomarker of C cell disease: recent achievements and current challenges. 61
31925733 2020
17
[Multiple endocrine neoplasia type 2A in a family]. 61
31902232 2020
18
Calcitonin-negative neuroendocrine tumor of the thyroid with metastasis to liver-rare presentation of an unusual tumor: A case report and review of literature. 61
31970185 2020
19
Long-term Clinicopathological Features of a Family with Multiple Endocrine Neoplasia Type 2A Caused by C634R RET Gene Mutation. 61
31949369 2020
20
Controversies in the surgical management of sporadic medullary thyroid carcinoma. 61
32011397 2020
21
Ultrasound features of ovarian recurrence of medullary thyroid carcinoma. 61
31994806 2020
22
The Diagnostic Value of Ultrasound in Medullary Thyroid Carcinoma: A Comparison With Computed Tomography. 61
32031054 2020
23
Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma. 61
31746350 2020
24
EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. 61
31482429 2020
25
The mismatch repair system is not affected in medullary thyroid carcinoma independent of stromal desmoplasia or ret proto-oncogene mutation. 61
31862521 2019
26
Prediction of lateral neck lymph node metastasis according to preoperative calcitonin level and tumor size for medullary thyroid carcinoma. 61
31483088 2019
27
The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review. 61
31301229 2019
28
Synchronous bilateral pheochromocytomas and bilobar medullary thyroid carcinoma revealed by 18F-FDOPA PET/CT in a MEN-2A asymptomatic patient. 61
31478160 2019
29
MEN 2B masquerading as chronic blepharitis and euryblepharon. 61
30688132 2019
30
Sarcopenia is a prognostic factor for TKIs in metastatic thyroid carcinomas. 61
31865555 2019
31
INCREASED SERUM CALCITONIN IN SPORADIC PRIMARY HYPERPARATHYROIDISM IS AN UNCOMMON OCCURRENCE. 61
31412223 2019
32
3D Printed Titanium Prosthetic Reconstruction of the C2 Vertebra: Techniques and Outcomes of 3 Consecutive Cases. 61
31809469 2019
33
[New aspects in thyroid cancer treatment : Highlights of the 2019 ASCO Annual Meeting]. 61
31628529 2019
34
Thyroid Tumors You Don't Want to Miss. 61
31672297 2019
35
Treatment of Aggressive Thyroid Cancer. 61
31672300 2019
36
The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment. 61
30782103 2019
37
Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma. 61
31549322 2019
38
Medullary thyroid carcinoma co-existent with Hashimoto's thyroiditis diagnosed by a comprehensive cytological approach. 61
31883317 2019
39
RET Proto-oncogene Gene Mutation Is Related to Cervical Lymph Node Metastasis in Medullary Thyroid Carcinoma. 61
31494787 2019
40
Calcitonin-negative medullary thyroid carcinoma: the 'triple-negative' phenotype. 61
31841033 2019
41
The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma. 61
31727170 2019
42
Clinical utility of 177 Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity. 61
31755622 2019
43
A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. 61
31650892 2019
44
[Imaging of medullary thyroid carcinoma]. 61
31367891 2019
45
Concomitant medullary thyroid carcinoma with paraganglioma-like pattern and papillary thyroid carcinoma. 61
31778356 2019
46
Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma. 61
31733124 2019
47
The role of postoperative adjuvant radiotherapy in the local control in medullary thyroid carcinoma. 61
31778360 2019
48
The KWAK TI-RADS and 2015 ATA guidelines for medullary thyroid carcinoma: Combined with cell block-assisted ultrasound-guided thyroid fine-needle aspiration. 61
31665550 2019
49
Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: Results from the largest MTC cohort and meta-analysis. 61
31408923 2019
50
Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center. 61
31145454 2019

Variations for Thyroid Gland Medullary Carcinoma

Cosmic variations for Thyroid Gland Medullary Carcinoma:

9 (show top 50) (show all 298)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88289588 VHL thyroid,NS,carcinoma,medullary carcinoma c.233A>T p.N78I 3:10142080-10142080 27
2 COSM87900604 TP53 thyroid,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 17:7674894-7674894 27
3 COSM89661857 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 27
4 COSM92347003 RET thyroid,NS,carcinoma,medullary carcinoma c.2753T>C p.M918T 10:43121968-43121968 27
5 COSM92354392 RET thyroid,NS,carcinoma,medullary carcinoma c.1902C>G p.C634W 10:43114502-43114502 27
6 COSM92351620 RET thyroid,NS,carcinoma,medullary carcinoma c.1888T>C p.C630R 10:43114488-43114488 27
7 COSM92349912 RET thyroid,NS,carcinoma,medullary carcinoma c.1901G>A p.C634Y 10:43114501-43114501 27
8 COSM92347669 RET thyroid,NS,carcinoma,medullary carcinoma c.1900T>A p.C634S 10:43114500-43114500 27
9 COSM92360468 RET thyroid,NS,carcinoma,medullary carcinoma c.2038G>A p.A680T 10:43114638-43114638 27
10 COSM92352088 RET thyroid,NS,carcinoma,medullary carcinoma c.1858T>C p.C620R 10:43113654-43113654 27
11 COSM92347226 RET thyroid,NS,carcinoma,medullary carcinoma c.1900T>C p.C634R 10:43114500-43114500 27
12 COSM92352166 RET thyroid,NS,carcinoma,medullary carcinoma c.2650G>A p.E884K 10:43120123-43120123 27
13 COSM92348232 RET thyroid,NS,carcinoma,medullary carcinoma c.1924G>A p.V642I 10:43114524-43114524 27
14 COSM92348203 RET thyroid,NS,carcinoma,medullary carcinoma c.1946C>T p.S649L 10:43114546-43114546 27
15 COSM92353521 RET thyroid,NS,carcinoma,medullary carcinoma c.2723G>A p.R908K 10:43120196-43120196 27
16 COSM92360348 RET thyroid,NS,carcinoma,medullary carcinoma c.2627C>T p.A876V 10:43120100-43120100 27
17 COSM92361758 RET thyroid,NS,carcinoma,medullary carcinoma c.2296C>T p.P766S 10:43118384-43118384 27
18 COSM92364859 RET thyroid,NS,carcinoma,medullary carcinoma c.1983C>T p.H661= 10:43114583-43114583 27
19 COSM92348533 RET thyroid,NS,carcinoma,medullary carcinoma c.2752A>C p.M918L 10:43121967-43121967 27
20 COSM92366466 RET thyroid,NS,carcinoma,medullary carcinoma c.2680G>A p.G894S 10:43120153-43120153 27
21 COSM92364868 RET thyroid,NS,carcinoma,medullary carcinoma c.2733T>G p.G911= 10:43121948-43121948 27
22 COSM92360413 RET thyroid,NS,carcinoma,medullary carcinoma c.1852T>C p.C618R 10:43113648-43113648 27
23 COSM92347631 RET thyroid,NS,carcinoma,medullary carcinoma c.2761G>A p.E921K 10:43121976-43121976 27
24 COSM92371499 RET thyroid,NS,carcinoma,medullary carcinoma c.2756C>T p.A919V 10:43121971-43121971 27
25 COSM92355531 RET thyroid,NS,carcinoma,medullary carcinoma c.2304G>C p.E768D 10:43118392-43118392 27
26 COSM92369676 RET thyroid,NS,carcinoma,medullary carcinoma c.1859G>C p.C620S 10:43113655-43113655 27
27 COSM92355833 RET thyroid,NS,carcinoma,medullary carcinoma c.2701G>A p.E901K 10:43120174-43120174 27
28 COSM92362032 RET thyroid,NS,carcinoma,medullary carcinoma c.1902C>T p.C634= 10:43114502-43114502 27
29 COSM92351674 RET thyroid,NS,carcinoma,medullary carcinoma c.2206G>A p.G736R 10:43116653-43116653 27
30 COSM92347663 RET thyroid,NS,carcinoma,medullary carcinoma c.1886T>A p.L629Q 10:43114486-43114486 27
31 COSM92348595 RET thyroid,NS,carcinoma,medullary carcinoma c.2647G>T p.A883S 10:43120120-43120120 27
32 COSM92371517 RET thyroid,NS,carcinoma,medullary carcinoma c.1892A>G p.D631G 10:43114492-43114492 27
33 COSM92361920 RET thyroid,NS,carcinoma,medullary carcinoma c.1888T>G p.C630G 10:43114488-43114488 27
34 COSM92350213 RET thyroid,NS,carcinoma,medullary carcinoma c.1858T>A p.C620S 10:43113654-43113654 27
35 COSM92363615 RET thyroid,NS,carcinoma,medullary carcinoma c.1853G>A p.C618Y 10:43113649-43113649 27
36 COSM92357762 RET thyroid,NS,carcinoma,medullary carcinoma c.2137G>A p.E713K 10:43116584-43116584 27
37 COSM92356468 RET thyroid,NS,carcinoma,medullary carcinoma c.2771T>C p.F924S 10:43121986-43121986 27
38 COSM92368621 RET thyroid,NS,carcinoma,medullary carcinoma c.2249C>G p.A750G 10:43116696-43116696 27
39 COSM92360106 RET thyroid,NS,carcinoma,medullary carcinoma c.1804A>G p.I602V 10:43113600-43113600 27
40 COSM92356863 RET thyroid,NS,carcinoma,medullary carcinoma c.2117T>C p.V706A 10:43114717-43114717 27
41 COSM92371161 RET thyroid,NS,carcinoma,medullary carcinoma c.2242G>T p.G748C 10:43116689-43116689 27
42 COSM92354502 RET thyroid,NS,carcinoma,medullary carcinoma c.2180G>A p.G727E 10:43116627-43116627 27
43 COSM92355240 RET thyroid,NS,carcinoma,medullary carcinoma c.2256C>T p.Y752= 10:43116703-43116703 27
44 COSM92351910 RET thyroid,NS,carcinoma,medullary carcinoma c.2041C>T p.Q681* 10:43114641-43114641 27
45 COSM92347619 RET thyroid,NS,carcinoma,medullary carcinoma c.2732G>A p.G911D 10:43121947-43121947 27
46 COSM92352077 RET thyroid,NS,carcinoma,medullary carcinoma c.1843G>A p.E615K 10:43113639-43113639 27
47 COSM97107822 NRAS thyroid,NS,carcinoma,medullary carcinoma c.182A>T p.Q61L 1:114713908-114713908 27
48 COSM97107359 NRAS thyroid,NS,carcinoma,medullary carcinoma c.182A>G p.Q61R 1:114713908-114713908 27
49 COSM87161590 MGA thyroid,NS,carcinoma,medullary carcinoma c.1228G>T p.E410* 15:41696238-41696238 27
50 COSM97714722 MDC1 thyroid,NS,carcinoma,medullary carcinoma c.6266C>A p.T2089N 6:30700469-30700469 27

Expression for Thyroid Gland Medullary Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Medullary Carcinoma.

Pathways for Thyroid Gland Medullary Carcinoma

GO Terms for Thyroid Gland Medullary Carcinoma

Cellular components related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.23 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 RET

Biological processes related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.13 TG SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
2 G protein-coupled receptor signaling pathway GO:0007186 10.02 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 SST
3 negative regulation of cell proliferation GO:0008285 9.76 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 SST
4 forebrain development GO:0030900 9.71 SSTR4 SSTR3 SSTR2 SSTR1
5 cerebellum development GO:0021549 9.69 SSTR3 SSTR2 SSTR1
6 response to starvation GO:0042594 9.65 SSTR3 SSTR2 SSTR1
7 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.65 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
8 cellular response to estradiol stimulus GO:0071392 9.63 SSTR3 SSTR2 SSTR1
9 cellular response to glucocorticoid stimulus GO:0071385 9.62 SSTR5 SSTR4 SSTR3 SSTR2
10 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.56 NTRK1 CALCA
11 sympathetic nervous system development GO:0048485 9.55 NTRK1 GDNF
12 enteric nervous system development GO:0048484 9.54 RET GDNF
13 peristalsis GO:0030432 9.52 SSTR2 GDNF
14 hormone-mediated apoptotic signaling pathway GO:0008628 9.49 SSTR3 SST
15 neuropeptide signaling pathway GO:0007218 9.43 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 CALCA
16 somatostatin signaling pathway GO:0038170 9.02 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1

Molecular functions related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.8 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 CCKBR
2 hormone activity GO:0005179 9.56 TG SST GAST CALCA
3 peptide binding GO:0042277 9.55 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
4 neuropeptide binding GO:0042923 9.35 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
5 somatostatin receptor activity GO:0004994 9.02 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1

Sources for Thyroid Gland Medullary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....